Christopher Kimball

Cooley advised EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, on its definitive agreement to be acquired by AstraZeneca (London Stock Exchange/Nasdaq Stockholm/Nasdaq: AZN) for up to $1 billion on a cash- and debt-free basis.

Cooley advised Lovable Labs, a Sweden-based artificial intelligence startup, on its $15 million pre-Series A financing round. The round was led by Creandum, with participation from Visionaries Club and angel investors, including Charlie Songhurst (Meta Platforms board), Adam D’Angelo and Thomas Wolf (Hugging Face), and Erik Bernhardsson (Modal Labs).

Lawyers Kevin Rooney, Karem Jarada, Carl Min, Shelby Saunders, Rebecca Ross, Christopher Kimball and Karen Tsai led the Cooley team advising Lovable, with support from paralegal Chu Lee and transactional quantitative analyst Jake Ironfield.

Cooley advised Harvey, a domain-specific artificial intelligence (AI) platform for legal and professional services, on its $300 million Series D financing at a $3 billion valuation.

Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).

Cooley advised SiteOne Therapeutics, a biopharmaceutical company developing selective ion channel modulators for the treatment of pain, cough and other conditions, on its $100 million Series C financing.